CN102985072A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN102985072A
CN102985072A CN2011800201397A CN201180020139A CN102985072A CN 102985072 A CN102985072 A CN 102985072A CN 2011800201397 A CN2011800201397 A CN 2011800201397A CN 201180020139 A CN201180020139 A CN 201180020139A CN 102985072 A CN102985072 A CN 102985072A
Authority
CN
China
Prior art keywords
compositions
sodium
efavirenz
polyoxyethylene
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800201397A
Other languages
English (en)
Chinese (zh)
Inventor
A·卢拉
G·马尔霍特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CN102985072A publication Critical patent/CN102985072A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800201397A 2010-04-20 2011-04-20 药物组合物 Pending CN102985072A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1296MU2010 2010-04-20
IN1296/MUM/2010 2010-04-20
PCT/GB2011/000620 WO2011131943A2 (en) 2010-04-20 2011-04-20 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN102985072A true CN102985072A (zh) 2013-03-20

Family

ID=44625957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800201397A Pending CN102985072A (zh) 2010-04-20 2011-04-20 药物组合物

Country Status (13)

Country Link
US (1) US20130302415A1 (https=)
EP (1) EP2560617A2 (https=)
JP (1) JP2013525337A (https=)
KR (1) KR20130076818A (https=)
CN (1) CN102985072A (https=)
AU (1) AU2011244783B2 (https=)
BR (1) BR112012026843A2 (https=)
CA (1) CA2796494A1 (https=)
GT (1) GT201200284A (https=)
NZ (1) NZ602955A (https=)
RU (1) RU2012149115A (https=)
WO (1) WO2011131943A2 (https=)
ZA (1) ZA201207670B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224790A (zh) * 2014-09-28 2014-12-24 苏州普罗达生物科技有限公司 一种依法韦仑组合物及其制备方法
CN112245400A (zh) * 2020-11-10 2021-01-22 蓝龙药业(北京)有限公司 一种依法韦仑微片剂、制备方法及其应用
CN114404377A (zh) * 2022-01-10 2022-04-29 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115633D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
IN2013MU03370A (https=) 2013-10-25 2015-09-25 Cipla Ltd
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IN2014MU00916A (https=) * 2014-03-20 2015-09-25 Cipla Ltd
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
US11654112B2 (en) 2016-11-22 2023-05-23 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
AU2018306303A1 (en) * 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
US20230040901A1 (en) * 2018-01-04 2023-02-09 PlantTec Medical GmbH Pharmaceutical composition for inhibiting postoperative adhesions
ES2732498B2 (es) * 2018-05-21 2020-04-27 Consejo Superior Investigacion Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico.
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
JP7522655B2 (ja) * 2018-06-11 2024-07-25 大塚製薬株式会社 デラマニド含有組成物
EP3917500A2 (en) 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
WO2021050953A1 (en) 2019-09-13 2021-03-18 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
AU2020395495B2 (en) * 2019-12-02 2024-05-09 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine
JP2023522627A (ja) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド 連続的な液滴形成及び脱水によって粒子を形成する方法
US20210330683A1 (en) * 2020-04-20 2021-10-28 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332757A1 (en) * 1998-05-27 2003-08-06 MERCK & CO. INC. Efavirenz compressed tablet formulation
CN101252921A (zh) * 2005-06-29 2008-08-27 惠氏公司 轭合雌激素类物质和苯卓昔芬的制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
US20080026062A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
TWI405590B (zh) * 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
US20090088424A1 (en) * 2007-08-17 2009-04-02 Ilan Zalit Methods and compositions for controlling the bioavailability of poorly soluble drugs
JP4606444B2 (ja) * 2007-08-21 2011-01-05 アピ株式会社 アントシアニン含有経口投与用組成物及びその製造方法
WO2010068899A1 (en) * 2008-12-12 2010-06-17 Creighton University Nanoparticles comprising combinations of antiretroviral agents and use thereof
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332757A1 (en) * 1998-05-27 2003-08-06 MERCK & CO. INC. Efavirenz compressed tablet formulation
CN101252921A (zh) * 2005-06-29 2008-08-27 惠氏公司 轭合雌激素类物质和苯卓昔芬的制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
崔福德: "《药剂学》", 31 July 2005, 人民卫生出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224790A (zh) * 2014-09-28 2014-12-24 苏州普罗达生物科技有限公司 一种依法韦仑组合物及其制备方法
CN112245400A (zh) * 2020-11-10 2021-01-22 蓝龙药业(北京)有限公司 一种依法韦仑微片剂、制备方法及其应用
CN112245400B (zh) * 2020-11-10 2023-01-20 蓝龙药业(北京)有限公司 一种依法韦仑微片剂、制备方法及其应用
CN114404377A (zh) * 2022-01-10 2022-04-29 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Also Published As

Publication number Publication date
EP2560617A2 (en) 2013-02-27
AU2011244783A1 (en) 2012-11-01
ZA201207670B (en) 2013-05-29
WO2011131943A8 (en) 2012-11-29
RU2012149115A (ru) 2014-05-27
KR20130076818A (ko) 2013-07-08
CA2796494A1 (en) 2011-10-27
US20130302415A1 (en) 2013-11-14
GT201200284A (es) 2014-08-26
AU2011244783B2 (en) 2015-11-12
JP2013525337A (ja) 2013-06-20
WO2011131943A3 (en) 2011-12-29
BR112012026843A2 (pt) 2016-07-12
NZ602955A (en) 2015-02-27
WO2011131943A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
CN102985072A (zh) 药物组合物
CN105246598B (zh) 乙酸阿比特龙酯制剂
CN103209687A (zh) 包含地拉罗司的药物组合物
DK2421540T3 (en) Hitherto unknown formulation with meloxicam
KR102617537B1 (ko) 아비라테론 아세테이트 제제 및 사용 방법
US20100168247A1 (en) Solid composites of a calcium receptor-active compound
CN101801347A (zh) 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法
US20150246060A1 (en) Abiraterone Acetate Formulation and Methods of Use
CN103221032A (zh) 药物组合物
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
US20060013871A1 (en) Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
MX2012012084A (es) Composicion farmaceutica.
EP4626434A1 (en) Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide
AU2014203359B2 (en) A Novel Formulation of Meloxicam
OA16350A (en) Pharmaceutical composition comprising deferasirox.
OA16372A (en) Reclaimer machine.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130320